000849537 001__ 849537
000849537 005__ 20210129234147.0
000849537 0247_ $$2doi$$a10.3238/arztebl.2018.0356
000849537 0247_ $$2pmid$$apmid:29914619
000849537 0247_ $$2WOS$$aWOS:000435360200008
000849537 0247_ $$2altmetric$$aaltmetric:43907947
000849537 037__ $$aFZJ-2018-03720
000849537 082__ $$a610
000849537 1001_ $$0P:(DE-HGF)0$$aGoldbrunner, Roland$$b0$$eCorresponding author
000849537 245__ $$aThe treatment of gliomas in adulthood
000849537 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2018
000849537 3367_ $$2DRIVER$$aarticle
000849537 3367_ $$2DataCite$$aOutput Types/Journal article
000849537 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1547048124_3111
000849537 3367_ $$2BibTeX$$aARTICLE
000849537 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000849537 3367_ $$00$$2EndNote$$aJournal Article
000849537 520__ $$aBackground: Gliomas are the most common intrinsic tumors of the brain, with an incidence of 6 per 100 000 persons per year. Recent years have seen marked changes in the diagnosis and treatment of gliomas, with molecular parameters now being an integral part of the diagnostic evaluation.Methods: This review is based on pertinent articles retrieved by a selective search in PubMed, with special attention to the new WHO glioma classification.Results: The classification of gliomas on the basis of additional molecular parameters enables more accurate prognostication and serves as a basis for therapeutic decision-making and treatment according to precisely specified algorithms. PET scanning with 18F-fluoroethyl tyrosine and 11C-methionine for the measurement of metabolic activity in gliomas has further refined the diagnostic evaluation. The median overall survival of patients with glioblastoma who have undergone resection of all tumor tissue with a disrupted blood–brain barrier (i.e., all contrast-enhancing tumor tissue) has been prolonged to up to 20 months. The 5-year survival of patients with WHO grade II gliomas is now as high as 97% after near-total resection. The surgical resection of all contrast-enhancing tumor tissue and subsequent radiotherapy and chemotherapy remain the key elements of treatment. New surgical strategies and new methods of planning radiotherapy have made these techniques safer and more effective. The percutaneous application of tumor-treating fields is a new therapeutic option that has gained a degree of acceptance. Accompanying measures such as psycho-oncology and palliative care are very important for patients and should be considered mandatory.Conclusion: The consistent application of the existing multimodal treatment options for glioma has led in recent years to improved survival. Areas of important current and future scientific activity include immunotherapy and targeted and combined chemotherapy, as well as altered neurocognition, modern approaches to palliative care, and complementary therapies.
000849537 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000849537 588__ $$aDataset connected to CrossRef
000849537 7001_ $$0P:(DE-HGF)0$$aRuge, Maximilian$$b1
000849537 7001_ $$0P:(DE-HGF)0$$aKocher, Martin$$b2
000849537 7001_ $$0P:(DE-HGF)0$$aLucas, Carolin Weiß$$b3
000849537 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b4
000849537 7001_ $$0P:(DE-HGF)0$$aGrau, Stefan$$b5
000849537 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.2018.0356$$n20-21$$p356-364$$tDeutsches Ärzteblatt international$$v115$$x1866-0452$$y2018
000849537 8564_ $$uhttps://juser.fz-juelich.de/record/849537/files/m356.pdf$$yRestricted
000849537 909CO $$ooai:juser.fz-juelich.de:849537$$pVDB
000849537 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b4$$kFZJ
000849537 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000849537 9141_ $$y2018
000849537 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2015
000849537 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000849537 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000849537 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000849537 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000849537 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000849537 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000849537 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000849537 920__ $$lyes
000849537 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000849537 980__ $$ajournal
000849537 980__ $$aVDB
000849537 980__ $$aI:(DE-Juel1)INM-3-20090406
000849537 980__ $$aUNRESTRICTED